SREBP-1c Gene Polymorphism is Associated with Increased Inhibition of Cholesterol-Absorption in Response to Ezetimibe Treatment

Abstract

Objective: Sterol regulatory binding proteins 1 and 2 (SREBPs) are transcription factors regulating lipid metabolism. A recent study has associated the CC genotype of the SREBP-1c polymorphism G952G with increased cholesterol synthesis. Further evidence suggests that SREBPs play a role in cholesterol absorption and that SREBP polymorphisms modulate the response to statin therapy. The present study examines whether the G952G polymorphism alters cholesterol synthesis and/or absorption and whether it modulates the response to widely used lipid-lowering drugs such as inhibitors of cholesterol synthesis (simvastatin) or absorption (ezetimibe).

Methods: Seventy-two healthy male subjects with LDL cholesterol <190 mg/dL participated in the study. Twenty four subjects were treated with ezetimibe (10 mg), simvastatin (40 mg) or their combination, respectively, for two weeks. Blood was drawn before and after the 2-week treatment period.

Results: Eleven CC homozygous carriers of the gene were found (15%).There were no differences in cholesterol synthesis or absorption between the CC homozygotes and the G allele-carriers, as measured by the ratios to cholesterol of serum lathosterol, desmosterol and cholestenol (synthesis markers) and cholestanol, sitosterol and campesterol (absorption markers). Ezetimibe had a significantly more potent effect in blocking cholesterol absorption in the CC homozygotes compared to the G-carriers (P=0.002).

Conclusions: The G/C (G952G) polymorphism of the SREBP-1 gene is not associated with cholesterol synthesis or absorption in a German male population. The CC homozygotes have a significantly increased response to the effects of ezetimibe on cholesterol absorption compared to the G allele-carriers, suggesting that SREBP-1 may be implicated in ezetimibe's mechanism of action.

Key words

SREBP - cholesterol - lathosterol - campesterol - genetic variant - ezetimibe - statin

References

• 1 Alrefai W, Annaba F, Sarwar Z. et al . Modulation of human Niemann-Pick C1 like gene expression by sterol: role of sterol regulatory elements binding protein-2.  Am J Physiol Gastrointest Liver Physiol epub ahead of print. 2006; 
• 2 Davidson MH, MacGarry T, Bettis R, Melani L, Lipka LJ, Lebeaut AP, Suresh R, Sun S, Veltri EP. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia.  J Am Coll Cardiol. 2002;  40 2125-2134
• 3 Duan X, Zhu W, Li Y, Zhang Z, Zhao Y, Dao Y, Xiao Y. The effect of sterol regulatory element-binding protein 2 polymorphism on the serum lipid in northern Chinese subjects.  J Lipid Res. 2005;  46 252-257
• 4 Ducluzeau PH, Perretti N, Laville M, Andreelli F, Vega N, Riou JP, Vidal H. Regulation by insulin of gene expression in human skeletal muscle and adipose tissue. Evidence for specific defects in type 2 diabetes.  Diabetes. 2001;  50 1134-1142
• 5 During A, Dawson HD, Harrison EH. Carotenoid transport is decreased and expression of the lipid transporters SR-BI, NPC1L1, and ABCA1 is downregulated in Caco-2 cells treated with ezetimibe.  J Nutr. 2005;  135 2305-2312
• 6 Eberle D, Clement K, Meyre D, Sahbatou M, Vaxillaire M, Gall A Le, Ferre P, Basdevant A, Froguel P, Foufelle F. SREBF-1 gene polymorphisms are associated with obesity and type 2 diabetes in French obese diabetic cohorts.  Diabetes. 2004a;  53 2153-2157
• 7 Eberle D, Hegarty B, Bossard P, Ferre P, Foufelle F. SREBP transcription factors: master regulators of lipid homeostasis.  Biochimie. 2004b;  86 839-848
• 8 Espenshade P, Li W, Yabe B. Sterols block binding of COPII proteins to SCAP, thereby controlling SCAP sorting in ER.  Proc Natl Acad Sci USA. 2002;  99 11694-11699
• 9 Fiegenbaum M, Silveira FR, Sand CR Van der, Sand LC Van der, Ferreira ME, Pires RC, Hutz MH. Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a and SREBF-2 genes.  Pharmacogenomics J. 2005;  5 359-364
• 10 Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR, Dean DC, Detmers PA, Graziano MP, Hughes M, Macintyre DE, Ogawa A, O'Neill KA, Iyer SP, Shevell DE, Smith MM, Tang YS, Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, Thornberry NA. The target of ezetimbe is Niemann-Pick C1-Like 1 (NPC1L1).  Proc Natl Acad Sci USA. 2005;  102 8132-8137
• 11 Hegele RA, Guy J, Ban MR, Wang J. NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe.  Lipids Health Dis. 2005;  4 16
• 12 Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies.  Genet Med. 2002;  4 45-61
• 13 Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver.  J Clin Invest. 2002;  109 1125-1131
• 14 Ketomaki A, Gylling H, Miettinen TA. Effects of plant stanol and sterol esters on serum phytosterols in a family with familial hypercholesterolemia including a homozygous sugject.  J Lab Clin Med. 2004;  143 255-262
• 15 Knight BL, Patel DD, Humphreys SM, Wiggins D, Gibbons GF. Inhibition of cholesterol absorption associated with a PPARa-dependent increase in ABC binding cassette transporter A1 in mice.  J Lipid Res. 2003;  44 2049-2058
• 16 Laaksonen R, Thelen KM, Päiva H, Matinheikki J, Vesalainen R, Janatuinen T, Knuuti J, Rontu R, Bergmann K von, Lütjohann D, Lehtimäki T. Genetic variant of the SREBF-1 gene is significantly related to cholesterol synthesis in man.  Atherosclerosis. 2006;  185 206-209
• 17 Laudes M, Baroso I, Luan J, Soos MA, Yeo G, Meirhaeghe A, Logie L, Vidal-Puig A, Schafer AJ, Wareham NJ, O'Rahilly S. Genetic variants in human sterol regulatory element binding protein-1c in syndromes of severe insulin resistance and type 2 diabetes.  Diabetes. 2004;  53 482-486
• 18 Miettinen TA, Tilvis RS, Kesaniemi YA. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population.  Am J Epidemiol. 1990;  131 20-31
• 19 Miserez A, Muller P, Barella L, Schwietert M, Erb P, Vernazza P, Battegay M. A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinemia.  AIDS. 2001;  15 2045-2049
• 20 Miserez AR, Muller PY, Barella L, Barella S, Staehelin HB, Leitersdorf E, Kark JD, Friedlander Y. Sterol-regulatory element-binding protein (SREBP)-2 contributes to polygenic hypercholesterolemia.  Atherosclerosis. 2002;  164 15-26
• 21 Muller PY, Miserez AR. Identification of mutations in the gene encoding sterol regulatory element binding protein (SREBP)-2 in hypercholesterlaemic subjects.  J Med Genet. 2002;  39 271-275
• 22 Osborne TF. Sterol regulatory element-binding proteins (SREBPs): key regulators of nutritional homeostasis and insulin action.  J Biol Chem. 2000;  275 32379-32382
• 23 Rios DL, Vargas AF, Torres MR, Zago AJ, Callegari-Jacques SM, Hutz MH. Interaction between SREBP-1a and APOB polymorphisms influences total and low-density lipoprotein cholesterol levels in patients with coronary artery disease.  Clin Genet. 2003;  63 380-385
• 24 Robinet P, Vedie B, Chironi G, Gariepy J, Simon A, Moatti N, Paul JL. Characterization of polymorphic structure of SREBP-2 gene: role in atherogenesis.  Atherosclerosis. 2003;  168 381-387
• 25 Salek L, Lutucuta S, Ballantyne CM, Gotto Jr A, Marian AJ. Effects of SREBP-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin.  J Mol Med. 2002;  80 737-744
• 26 Sane AT, Sinnett D, Delvin E, Bendayan M, Marcil V, Menard D, Beaulieu J-F, Levy E. Localization and role of NPC1L1 in cholesterol absorption in human intestine.  J Lipid Res. 2006;  47 2112-2120
• 27 Sewter C, Berger D, Considine RV, Medina G, Rochford J, Ciaraldi T, Henry R, Dohm L, Flier JS, O'Rahilly S, Vidal-Puig AJ. Human obesity and type 2 diabetes are associated with alterations in SREBP1 isoform expression that are reproduced ex vivo by tumor necrosis factor-alpha.  Diabetes. 2002;  51 1035-1041
• 28 Shimomura I, Bashmakov Y, Shimano H, Horton JD, Goldstein JL, Brown MS. Cholesterol feeding reduces nuclear forms of sterol regulatory element binding proteins in hamster liver.  Proc Natl Acad Sci USA. 1997;  94 12354-12359
• 29 Simon JS, Karnoub MC, Devlin DJ, Arreaza MG, Qiu P, Monks SA, Severino ME, Deutsch P, Palmisano J, Sachs AB, Bayne ML, Plump AS, Schadt EE. Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment.  Genomics. 2005;  86 648-656
• 30 Vedie B, Jeunemaitre X, Megnien JL, Atger V, Simon A, Moatti N. A new DNA polymorphism in the 5′ untranslated region of the human SREBP-1a is related to development of atherosclersis in high cardiovascular risk population.  Atherosclerosis. 2001;  154 589-597
• 31 Wang J, Williams CM, Hegele RA. Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe.  Clin Genet. 2005;  67 175-177
• 32 Yang A, King MS, Han L, Isaacson JD, Mueller T, Grimm DR, Brun SC, Katz DA. Lack of correlation between SREBF1 genotype and hyperlipidemia in individuals treated with highly active antiretroviral therapy.  AIDS. 2003;  17 2142-2143

Correspondence